• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
By STEPHEN GUILFOYLE
Nov 01, 2019 | 08:20 AM EDT
Stocks quotes in this article: GM, XLV, CNC, CI, UNH, HUM, AMGN, MRK, ABBV, BGNE, BABA, CVX, XOM, STX, CACC

Of Wolf And Man

Shape Shift, Nose To The Wind

Shape Shift, Feeling I Have Been

Move Swift, All Senses Clean

Earth's Gift, Back To The Meaning

Back To The Meaning of Wolf And Man

- Metallica 1991

The Hunt

The hunt. For stocks? For truth. What is truth? A down day for equities on Thursday seemed to almost shock traders, as if it were some kind of rude slap in the face. Silly? Of course. Then, again, markets often overshoot and then correct. This is what passes for price discovery in 2019 in our perversely fractured, intentionally opaque marketplace. You do already know that you were conditioned so as not to trust a centralized marketplace where traders on both sides had to identify themselves on every trade by audibly announcing not only their badge numbers, but also the sell side firm that they were "giving up" on that particular trade, right? Did not feel like speaking up? You bought and sold exactly nothing. Transparent? To say the least.

Even with the silly games now played, we see them racing. We see them because we try harder than they do. We watch their repetition. We see their sniper programs. We laugh as they force each other up or down to levels that mock the concept of price discovery. Oh they are far too quick for humans to compete with on speed. So it is that we compete on price. For they have forgotten about price, they only hunt profit measured in micro-seconds. While they rely upon their programs to do this, they read the sports pages, or laugh at 13 year-olds falling off of skateboards on YouTube. They have forgotten that they need to fight us. I laugh at the folly.

Equity indices up? Equity indices down? Not only do they not know, they don't care. As long as the machine keeps doing what it's doing. We know that the retiree still cares about price. We know that the parent trying to pay a king's ransom for tuition still cares about price. We know that the six month old who has no idea, needs us to care about price. Real price discovery is not measured in micro-seconds. Price discovery is measured in dollars and cents. It may come in the form of lightning. It may not come very quickly at all. Price discovery does need to be taken seriously. This requires buyers and sellers to seek each other out and have conversations. In the light. Out loud. Until then, we hunt.

Land Navigation

Equity markets finally took a breather on Thursday. That was to be expected. I mean, seriously. The S&P 500 had run 2% over the past month. From the trough on October 3rd to the peak close on Wednesday, that run was more like 6.8%. I've been through a few rough Octobers in my day. When my name is mentioned for the last time, this will not have been one of them.

It happened early. Bloomberg TV reported that the Chinese side might think that a long-term deal with the U.S. might be beyond reach. My thought might be let's just get a Phase One agreement signed before worrying about a more comprehensive deal, but a match had been lit. Moving on, the House of Representatives passed strictly along partisan lines, a resolution to initiate the public phase of an impeachment inquiry into the President of the United States. The lit match had found kindling. Algorithms love political risk.

A lot was also made of the very weak October print for the Chicago PMI that showed a collapse in New Orders as well as Order Backlogs. I have written often on the Chicago PMI as a data-point. The series is well known among economists as wildly volatile, and often misses and/or beats consensus by wide margins. Somehow, the street for the most part failed to incorporate the General Motors (GM) strike into the collective rationale when considering this survey. They'll likely see some impact, but on the national level when the ISM survey hits the tape later on Friday. Before that, traders will have to do the whole dog and pony show that the BLS brings with it on "Jobs Day." Psst... the GM strike could show up here too. The algos will do their thing. We will keep our heads about us.

Trading volume exploded to the upside on Thursday at both of New York's exchanges. Meaningful distribution? I have some doubts. One day after the Fed, one day ahead of the BLS, last day of an "up" month. Markets rallied hard into the close, which is when the most trading volume occurred. As per usual. Still, for the day, declining volume did beat advancing volume by roughly two to one.

Watching Health Care

Health Care. The Select Sector SPDR ETF (XLV) soared 5.13% over the past month. The sector in aggregate trades at less than 15 times forward earnings versus more than 17 for the S&P 500. Yup. Health Care providers had a pretty good month.

That's what +11.6% in a month looks like. Centene (CNC) screamed 22% higher to the period. Cigna (CI) , UnitedHealthcare (UNH) , and Humana (HUM) all ran between 15% and 17% if you're stuck for names to consider. How about Big Pharma? Or Bio-Tech? Talk about political risk? Suddenly not so sure. I mean, of course. The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle. The space is a political football. Unless, being forced by the machinery of modern politics, these folks down in DC forget to do the work of the people. Will the need to either vilify or defend the president 'trump' other concerns? Those concerns include funding the government. Funding defense. Plenty to distract.

At more pedestrian October growth of 4%, this group moves just a bit under the radar. Bio-Tech as a group has been even stronger, +6.5% for the month.

Still, extremely low multiples. Extremely high margins. Cash flows. Dividends. There 's a lot to like, at least for investors. My current longs in these industries are Amgen (AMGN) , Merck (MRK) , and AbbVie (ABBV) . Plenty of others look fine, too. While I want exposure, I also don't want to get overexposed. I did just tell you that this is a political football. That reminds me...

What Was That?

BeiGene (BGNE) soared after the close on Thursday evening. American Depository Receipts of this Chinese BioPharma closed at $138.34. The last sale that I see (it's still dark and will be for a while) is an even $175. What gives is an announced collaboration with Amgen in the development and commercialization of various cancer therapies.

The results of this complicated agreement are that the two firms will go to market with Amgen's Xgeva (bone health), Kyprolis (cancer) and Blincyto (cancer) in China over the next five to seven years sharing equally the profits/losses. The two firms will also work toward developing 20 other Amgen cancer treatments with BeiGene taking care of the Chinese side of this work. As part of the arrangement, Amgen will take a 20.5% stake in BeiGene for roughly $2.7 billion, or $174.85 per ADR.

Now, Amgen which was up a percent on Thursday, has not really traded off overnight. Should weakness develop on Friday in response to this capital outlay, this would interest me as an investor.

I will tell you what I see, and then what I think might develop. I see a basing period after a rise in price. This is framed in orange, and the shares appear to be breaking out from a pivot of $211. Now, should there be a controlled selloff in response to this news, the base would then become a cup, the selloff that has not happened yet? A handle. Still with me? This is where hopefully a discount comes in.

Now, see that 50 day SMA? That line does get pierced from time to time, but never for that long. That spot is now at $200. That's where I would love to add. We get that move, and then out pivot moves from the $211 high of late August to the $213 level which would then be the right side of the cup. (The top of the right side of a cup is always considered a pivot, meaning that it either becomes resistance, or a springboard for a breakout.)

Amgen 

- Target Price: 255

- Add: 200

- Panic: 196 (up from 192)

October Employment Situation (08:30 ET)

Non-Farm Payrolls: Expecting 91K, Last 136K.

Average Hourly Earnings: Expecting 3.0% y/y, Last 2.9% y/y.

Average Weekly Hours: Expecting 34.4, Last 34.4 hours.

Participation Rate: Expecting 63.2%, Last 63.2%.

Unemployment Rate: Expecting 3.6%, Last 3.5%.

Underemployment Rate: Last 6.9%.

Other Economics (All Times Eastern)

09:45 - Markit Manufacturing PMI (Oct-F): Flashed 51.5.

10:00 - ISM Manufacturing Index (Oct): Expecting 48.9, Last 47.8.

10:00 - Construction

Spending (Sep): Expecting 0.2% m/m, Last 0.1% m/m.

13:00 - Baker Hughes Oil Rig Count (Weekly): Last 696.

The Fed (All Times Eastern)

13:00 - Speaker: Reserve Board Gov. Randal Quarles.

13:00 - Speaker: Reserve Board Gov. Richard Clarida.

12:30 - Speaker: New York Fed Pres. John Williams.

Today's Earnings Highlights (Consensus EPS Expectations)

Before the Open: ABBV (2.30), (BABA) (10.68), (CVX) (1.51), (XOM) (.66), (STX) (.99)

After the Close: (CACC) (8.90)

(UnitedHealth and AbbVie are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long ABBV, CVX, STX equity.

TAGS: Investing | Markets | Options | Politics | Stocks | Technical Analysis | Trading | Healthcare | Pharmaceuticals | China

More from Investing

XL Fleet's Charts Show Potential for a Future Purchase

Bruce Kamich
Mar 3, 2021 8:49 AM EST

A new base pattern needs to develop before taking a long position.

Hopping on a Couple Compelling Opportunities in a Market That Isn't

Bret Jensen
Mar 3, 2021 8:30 AM EST

Dips in the shares of Redhill Biopharma and FibroGen Inc. provided the chance for the author to employ his covered call strategy.

The Foundation for the Next Major Market Cycle Is Developing Now

James "Rev Shark" DePorre
Mar 3, 2021 7:55 AM EST

This corrective phase may go deeper, but we see some good support.

China's Rubber-Stamp Congress Set to Kick Off

Alex Frew McMillan
Mar 3, 2021 7:45 AM EST

Cracking down on Hong Kong and outlining plans for future growth are two key items on the agenda in Beijing.

Biden Bits, Vaccine Vanguard, Unmasking Folly, Minerd Musings, Ives Inklings

Stephen Guilfoyle
Mar 3, 2021 7:36 AM EST

Among other things, the president works to align Democratic senators to support his massive Covid relief bill.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:50 AM EST PAUL PRICE

    Michael's - Close to a deal?

    It appears that a deal could be announced soon. ...
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 3/3/2021

    SPX (Long-Term View) The 20 DMA @ 3889 with the ...
  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login